vs
Side-by-side financial comparison of AMICUS THERAPEUTICS, INC. (FOLD) and PROCORE TECHNOLOGIES, INC. (PCOR). Click either name above to swap in a different company.
PROCORE TECHNOLOGIES, INC. is the larger business by last-quarter revenue ($349.1M vs $185.2M, roughly 1.9× AMICUS THERAPEUTICS, INC.). AMICUS THERAPEUTICS, INC. runs the higher net margin — 0.9% vs -10.8%, a 11.7% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs 15.6%). PROCORE TECHNOLOGIES, INC. produced more free cash flow last quarter ($109.2M vs $16.0M). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs 13.8%).
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
Procore Technologies is an American construction management software as a service company founded in 2002, with headquarters in Carpinteria, California. Procore hosts a platform to connect those involved in the construction industry on a global platform. The software allows for the creation of simplified workflows and displays a consolidated view of construction products that includes the tracking of tasks, management of project workflows, and scheduling.
FOLD vs PCOR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $185.2M | $349.1M |
| Net Profit | $1.7M | $-37.6M |
| Gross Margin | 85.7% | 80.1% |
| Operating Margin | 8.6% | -12.3% |
| Net Margin | 0.9% | -10.8% |
| Revenue YoY | 23.7% | 15.6% |
| Net Profit YoY | -88.5% | 39.6% |
| EPS (diluted) | $0.00 | $-0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $185.2M | $349.1M | ||
| Q3 25 | $169.1M | $338.9M | ||
| Q2 25 | $154.7M | $323.9M | ||
| Q1 25 | $125.2M | $310.6M | ||
| Q4 24 | $149.7M | $302.0M | ||
| Q3 24 | $141.5M | $295.9M | ||
| Q2 24 | $126.7M | $284.3M | ||
| Q1 24 | $110.4M | $269.4M |
| Q4 25 | $1.7M | $-37.6M | ||
| Q3 25 | $17.3M | $-9.1M | ||
| Q2 25 | $-24.4M | $-21.1M | ||
| Q1 25 | $-21.7M | $-33.0M | ||
| Q4 24 | $14.7M | $-62.3M | ||
| Q3 24 | $-6.7M | $-26.4M | ||
| Q2 24 | $-15.7M | $-6.3M | ||
| Q1 24 | $-48.4M | $-11.0M |
| Q4 25 | 85.7% | 80.1% | ||
| Q3 25 | 88.5% | 79.7% | ||
| Q2 25 | 90.2% | 79.1% | ||
| Q1 25 | 90.7% | 79.1% | ||
| Q4 24 | 90.1% | 81.2% | ||
| Q3 24 | 90.6% | 81.4% | ||
| Q2 24 | 91.1% | 83.1% | ||
| Q1 24 | 87.7% | 83.0% |
| Q4 25 | 8.6% | -12.3% | ||
| Q3 25 | 20.3% | -4.4% | ||
| Q2 25 | -6.1% | -9.3% | ||
| Q1 25 | -6.3% | -11.7% | ||
| Q4 24 | 10.7% | -21.9% | ||
| Q3 24 | 15.3% | -12.3% | ||
| Q2 24 | 11.8% | -5.2% | ||
| Q1 24 | -25.1% | -7.0% |
| Q4 25 | 0.9% | -10.8% | ||
| Q3 25 | 10.2% | -2.7% | ||
| Q2 25 | -15.8% | -6.5% | ||
| Q1 25 | -17.3% | -10.6% | ||
| Q4 24 | 9.8% | -20.6% | ||
| Q3 24 | -4.8% | -8.9% | ||
| Q2 24 | -12.4% | -2.2% | ||
| Q1 24 | -43.9% | -4.1% |
| Q4 25 | $0.00 | $-0.25 | ||
| Q3 25 | $0.06 | $-0.06 | ||
| Q2 25 | $-0.08 | $-0.14 | ||
| Q1 25 | $-0.07 | $-0.22 | ||
| Q4 24 | $0.05 | $-0.42 | ||
| Q3 24 | $-0.02 | $-0.18 | ||
| Q2 24 | $-0.05 | $-0.04 | ||
| Q1 24 | $-0.16 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $293.5M | $768.5M |
| Total DebtLower is stronger | $392.7M | — |
| Stockholders' EquityBook value | $274.2M | $1.3B |
| Total Assets | $949.9M | $2.2B |
| Debt / EquityLower = less leverage | 1.43× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $293.5M | $768.5M | ||
| Q3 25 | $263.8M | $684.0M | ||
| Q2 25 | $231.0M | $620.9M | ||
| Q1 25 | $250.6M | $566.7M | ||
| Q4 24 | $249.9M | $775.4M | ||
| Q3 24 | $249.8M | $756.9M | ||
| Q2 24 | $260.1M | $735.4M | ||
| Q1 24 | $239.6M | $744.6M |
| Q4 25 | $392.7M | — | ||
| Q3 25 | $392.0M | — | ||
| Q2 25 | $391.3M | — | ||
| Q1 25 | $390.7M | — | ||
| Q4 24 | $390.1M | — | ||
| Q3 24 | $389.5M | — | ||
| Q2 24 | $388.9M | — | ||
| Q1 24 | $388.4M | — |
| Q4 25 | $274.2M | $1.3B | ||
| Q3 25 | $230.4M | $1.2B | ||
| Q2 25 | $204.3M | $1.2B | ||
| Q1 25 | $193.6M | $1.2B | ||
| Q4 24 | $194.0M | $1.3B | ||
| Q3 24 | $178.8M | $1.3B | ||
| Q2 24 | $132.5M | $1.3B | ||
| Q1 24 | $130.7M | $1.2B |
| Q4 25 | $949.9M | $2.2B | ||
| Q3 25 | $868.8M | $2.1B | ||
| Q2 25 | $815.3M | $2.0B | ||
| Q1 25 | $789.8M | $1.9B | ||
| Q4 24 | $785.0M | $2.1B | ||
| Q3 24 | $786.6M | $2.0B | ||
| Q2 24 | $749.5M | $2.0B | ||
| Q1 24 | $721.8M | $1.9B |
| Q4 25 | 1.43× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.92× | — | ||
| Q1 25 | 2.02× | — | ||
| Q4 24 | 2.01× | — | ||
| Q3 24 | 2.18× | — | ||
| Q2 24 | 2.93× | — | ||
| Q1 24 | 2.97× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.3M | $114.9M |
| Free Cash FlowOCF − Capex | $16.0M | $109.2M |
| FCF MarginFCF / Revenue | 8.6% | 31.3% |
| Capex IntensityCapex / Revenue | 0.2% | 1.6% |
| Cash ConversionOCF / Net Profit | 9.62× | — |
| TTM Free Cash FlowTrailing 4 quarters | $29.8M | $282.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.3M | $114.9M | ||
| Q3 25 | $35.7M | $88.5M | ||
| Q2 25 | $-26.5M | $30.8M | ||
| Q1 25 | $7.8M | $66.0M | ||
| Q4 24 | $-3.9M | $29.1M | ||
| Q3 24 | $-23.0M | $39.3M | ||
| Q2 24 | $22.7M | $58.7M | ||
| Q1 24 | $-29.7M | $69.1M |
| Q4 25 | $16.0M | $109.2M | ||
| Q3 25 | $35.3M | $83.1M | ||
| Q2 25 | $-28.9M | $27.9M | ||
| Q1 25 | $7.5M | $62.0M | ||
| Q4 24 | $-4.2M | $17.4M | ||
| Q3 24 | $-23.3M | $35.7M | ||
| Q2 24 | $21.6M | $56.8M | ||
| Q1 24 | $-31.5M | $67.1M |
| Q4 25 | 8.6% | 31.3% | ||
| Q3 25 | 20.9% | 24.5% | ||
| Q2 25 | -18.7% | 8.6% | ||
| Q1 25 | 6.0% | 20.0% | ||
| Q4 24 | -2.8% | 5.8% | ||
| Q3 24 | -16.5% | 12.1% | ||
| Q2 24 | 17.0% | 20.0% | ||
| Q1 24 | -28.5% | 24.9% |
| Q4 25 | 0.2% | 1.6% | ||
| Q3 25 | 0.2% | 1.6% | ||
| Q2 25 | 1.6% | 0.9% | ||
| Q1 25 | 0.2% | 1.3% | ||
| Q4 24 | 0.2% | 3.9% | ||
| Q3 24 | 0.3% | 1.2% | ||
| Q2 24 | 0.9% | 0.7% | ||
| Q1 24 | 1.6% | 0.8% |
| Q4 25 | 9.62× | — | ||
| Q3 25 | 2.06× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -0.27× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
PCOR
| US | $298.3M | 85% |
| Non Us | $50.9M | 15% |
